Recombinant Human OSM, 195a.a. (Recombinant Human Oncostatin-M, 195a.a.; rHuOSM, 195a.a.);重组人肿瘤抑制素M,195a.a.
Synonyms
MGC20461; oncostatin M; oncostatin-M
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 2ng/ml, corresponding to a specific activity of >5.0×105IU/mg.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH7.4.
Endotoxin
Less than 0.1EU/μg of rHuOSM, 195a.a. as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Oncostatin M (OSM) is a multifunctional cytokine that belongs to the Interleukin-6 subfamily. Among the family members, OSM is most closely related to leukemia inhibitory factor (LIF) and it in fact utilizes the LIF receptor in addition to its specific receptor in the human. A biologically active OSM receptor has been previously described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130. OSM is synthesized by stimulated T-cells and monocytes. The effects of OSM on endothelial cells suggest a pro-inflammatory role for OSM and endothelial cells possess a large number of OSM receptors. Recombinant human OSM (195a.a.) has approximately 46% and 45% amino acid sequence identity with rat and murine OSM.